This page/content is for Great Britain healthcare professionals only.
Pluvicto® is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor (AR) pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.1
Contact us
To contact a member of the Advanced Accelerator Applications (a Novartis Company) team, please click below to fill in the request form.
Pluvicto mechanism of action
Pluvicto targets PSMA-positive cells, including prostate cancer cells.1
Safety profile and efficacy
The efficacy and safety profile of Pluvicto + BSoC were assessed in the VISION trial.2
Dosing and administration
Pluvicto is a ready-to-use solution administered intravenously.1
AR, androgen receptor; BSoC, best standard of care; mCRPC, metastatic castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen.
References:
- Pluvicto® Great Britain Summary of Product Characteristics.
- Sartor O, et al. N Engl J Med 2021;385(12):1091–1103.